Role of Quality of Life in Health Technology Assessment Agency Final Recommendations: Insights and Lessons From Review of NICE Technology Assessment Reports (2019-2022)
Author(s)
Aggarwal S1, Bela A2, Topaloglu H2, Kumar S3, Topaloglu O1
1NOVEL Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA, 3NOVEL HEALTH STRATEGIES, COLUMBIA, MD, USA
OBJECTIVES:
Quality of life (QoL) is an important outcome for patients and caregivers. However, there is limited information on the role of QoL in influencing Health Technology Assessment (HTA) agency's final recommendations. The objective of this analysis was to understand role of QoL data in NICE's final recommendations.METHODS:
A systematic review of all 2019-2022 NICE HTAs was conducted using NOVEL-HTA database. Reports were categorized by therapeutic area indication (oncology, neurology, dermatology, inflammation, rare diseases, and others). Final recommendations were reviewed for key QoL evidence that NICE had cited. For selected reports, case studies were developed for insights, and lessons learned.RESULTS:
During 2019-June 2022, there were 148 HTA reports published by NICE. Vast majority of the reports were for oncology (53%), followed by rare diseases (11%), neurology (6%), arthritis (5%), dermatology (4%) metabolic (3%) and gastrointestinal diseases (2%). Thirteen (~9%) of all reviewed reports included Quality of Life as one of the key influencing criteria. Six (46%) of the 13 were for rare diseases, 4 were for neurology, 2 for oncology and 1 for metabolic disorders. In 5 assessments, NICE acknowledged QoL as one of the key benefits of the treatment. In two assessments, NICE mentioned that sponsor had missed the opportunity to include sibling related QoL benefits. In 4 assessments, NICE mentioned there was likely QoL benefit but there were issues in how the data was collected. In 2 assessments, NICE mentioned there was a lack of QoL data for the treatment.CONCLUSIONS:
To our knowledge this is the first report describing use of QoL data in influencing final HTA recommendation. Case studies highlight that in some settings QoL plays an important role in HTA recommendations, however, there is a need for better methods to fully capture QoL benefits of new treatments.Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Value in Health, Volume 25, Issue 12S (December 2022)
Code
HTA83
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Gastrointestinal Disorders, STA: Drugs